Psychiatr. pro Praxi, 2007; 4: 176-178

Sertindol a jeho príbeh

prof. MUDr. Vladimír Novotný CSc
Psychiatrická klinika FN a LF UK Bratislava

The article brings the latest information about sertindol. It shows brief information about pharmacokinetics and pharmacodynamics of the treatment, and its clinical effectiveness. We refer to studies dealing with side effects of medication. It discusses in detail QT interval and the history of related administrative problems.

Keywords: sertindol, pharmacodynamics, pharmacokinetics, tolerance and safety

Published: July 20, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný V. Sertindol a jeho príbeh. Psychiatr. praxi. 2007;8(4):176-178.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Agelink MW, Zeit T, Baumann B et al. In vivo cardiovascular effects of the new atypical sertindole. Int J Psych Clin Pract 2001, 5: 33-40. Go to original source... Go to PubMed...
    2. Azorin JM, Strub N, Loft H. A double-blind controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharm 2006, 21: 49-56. Go to original source... Go to PubMed...
    3. Daniel DG, Wozniak P, Mack RJ et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998, 34: 61-69. Go to PubMed...
    4. Fritze J, Bandelow B. The QT interval and atypical antipsychotic, sertindole. Int J Psych Clin Pract 1998, 2: 265-273. Go to original source... Go to PubMed...
    5. Hale A, Azorin JM, Kasper S et al. Sertindole improves both the positive and negative symptoms of schizophrenia: Results of phase III trial. Int J Psych Clin Pract 2000a, 4: 55-62. Go to original source... Go to PubMed...
    6. Hale A, Azorin JM, Kasper S et al. Sertindole associated with a low level of extrapyramidal symptoms in schizophrenic patients. Results of a phase III trial. Int J Psych Clin Pract 2000b, 4: 47-54. Go to original source... Go to PubMed...
    7. Lis S, Krieger S, Gallhofer B et. al. Sertindole is superior to haloperidol in cognitive performance íin patients with schizophrenia: a comparative study. Eur. Neuropsychopharm 2003, 13, Suppl 4: S323-S324. Go to original source...
    8. Kane J, Potkin S, Buckley P et al. Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia (poster). 10th International Congress on Schizophrenia research, Apr. 2005, Savannah, USA.
    9. Kasper S, Tuomi M. The clinical safety and tolerability profile of sertindole. Int J Neuropsychopharm 2004, 7, (Suppl.1): S422.
    10. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Clin Psych Pract 2002, 6, (Suppl 1): 53-59. Go to original source... Go to PubMed...
    11. Murdoch D, Keating GM. Sertindole. A review of its use in schizophrenia. CNS Drugs, 2006, 20: 233-255. Go to original source... Go to PubMed...
    12. Novotný V. Serdolect. Klinicko-farmakologický posudok. ŠÚKL, Bratislava, 1997.
    13. Nyberg S, Olsson H, Nilsson U. et al. Low striatal and extrastriatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindol. Psychopharmacology (Berl) 2002, 162: 37-41. Go to original source... Go to PubMed...
    14. Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs, 2004, Suppl. 2: 19-30. Go to original source... Go to PubMed...
    15. Švestka J. Nová antipsychotika: sertindol. Psychiatrie, 1998, 2: 174-180.
    16. Tamminga CA. Sertindole and schizophrenia. Current Medical Group, London, 2006.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.